Captrust Financial Advisors Acquires 701 Shares of ICON Public Limited (NASDAQ:ICLR)

Captrust Financial Advisors raised its stake in shares of ICON Public Limited (NASDAQ:ICLR) by 2.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,301 shares of the medical research company’s stock after buying an additional 701 shares during the quarter. Captrust Financial Advisors’ holdings in ICON Public were worth $7,403,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of ICLR. Tributary Capital Management LLC grew its stake in ICON Public by 116.1% during the fourth quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company’s stock valued at $828,000 after acquiring an additional 2,122 shares in the last quarter. GAMMA Investing LLC grew its position in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after purchasing an additional 169 shares in the last quarter. Entropy Technologies LP increased its holdings in shares of ICON Public by 472.2% in the fourth quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock worth $1,295,000 after purchasing an additional 5,095 shares during the last quarter. Natixis Advisors LLC lifted its position in shares of ICON Public by 6.7% in the fourth quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company’s stock worth $37,279,000 after buying an additional 11,177 shares in the last quarter. Finally, Motley Fool Wealth Management LLC boosted its stake in ICON Public by 2.3% during the fourth quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company’s stock valued at $13,342,000 after buying an additional 1,466 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Price Performance

ICLR opened at $138.42 on Friday. The company has a quick ratio of 1.34, a current ratio of 1.26 and a debt-to-equity ratio of 0.36. The business has a fifty day moving average of $160.92 and a 200 day moving average of $191.85. ICON Public Limited has a 52-week low of $133.28 and a 52-week high of $347.72. The stock has a market cap of $11.18 billion, a P/E ratio of 14.52, a PEG ratio of 1.86 and a beta of 1.23.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, April 30th. The medical research company reported $3.19 EPS for the quarter, topping the consensus estimate of $3.17 by $0.02. The company had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.03 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The firm’s revenue was down 4.3% compared to the same quarter last year. During the same quarter last year, the firm posted $3.47 EPS. As a group, sell-side analysts anticipate that ICON Public Limited will post 13.38 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. The Goldman Sachs Group decreased their price objective on ICON Public from $180.00 to $160.00 and set a “neutral” rating on the stock in a report on Friday, May 2nd. TD Cowen lowered shares of ICON Public from a “buy” rating to a “hold” rating and lowered their price objective for the company from $254.00 to $157.00 in a research report on Monday, April 14th. Mizuho reduced their target price on shares of ICON Public from $238.00 to $200.00 and set an “outperform” rating on the stock in a report on Wednesday, April 9th. JPMorgan Chase & Co. downgraded shares of ICON Public from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $265.00 to $150.00 in a report on Tuesday, April 29th. Finally, Robert W. Baird reduced their price objective on ICON Public from $192.00 to $160.00 and set a “neutral” rating on the stock in a research note on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, ICON Public presently has an average rating of “Moderate Buy” and a consensus target price of $215.33.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.